KIDS sells, 3i funds VBIO, and GeoPark moves toward control (2026)

The disclosure window runs from September 1, 2026 at 8:00 a.m. through September 8, 2026 at 8:00 a.m. (UTC-05:00). The filings below became available during that window, while each entry keeps its underlying transaction, event, or measurement date separate. The useful question for a retail trader is what kind of evidence each filing provides: an executed trade, a financing position, a control event, a governance stance, a distribution, or a passive ownership map.

Quick scan

Ticker and holder	Filing availability / underlying date	Disclosed change	Remaining stake or structure	Follow-up question
KIDS — Squadron Capital	Sep. 1 / sales Aug. 24-Aug. 28 and Sep. 1	Sold 375,131 shares at weighted-average prices from $23.04 to $25.75	6,526,633 shares, 25.0% direct ownership	Is the roughly 25% holder still selling? 1
VBIO — 3i and affiliates	Sep. 2 / Aug. 31	Bought preferred stock and warrants in a financing with $7,737,000 aggregate purchase price	133,005 shares or issuable shares, 9.9%, subject to a 9.99% cap	How much exposure becomes common stock after conversion or exercise? 2
GPRK — Colden Investments and Jaime Gilinski	Sep. 4 / Sep. 2	Proposed GeoPark acquisition of 95% of Energy Assets International, with newly issued shares and a later tender offer	27.6% for Colden and 27.9% for Gilinski; closing conditions remain	Do approvals, the production contract, and the tender offer move forward? 3
VNRX — Lagoda Investment Management	Sep. 4 / Aug. 17	Shifted from 13G to 13D and disclosed a management-supporting board letter	1,652,005 shares, 7.4%, including 171,055 warrant shares	What governance proposals or cost actions follow? 4
ETOR — Spark Capital entities	Sep. 4 / Aug. 12	Distributed 3,582,287 shares pro rata without consideration; sold 5,783 shares at a weighted average of $28.01	Spark entities report zero beneficial ownership; Santo Politi retained 2,107 shares	Was the distribution followed by any new market selling? 5
FBIO — Millennium-linked entities	Sep. 1 / Aug. 26	Reported 5.3% ownership at the threshold	Shared voting and dispositive power; no transaction schedule disclosed	Does a later filing disclose a transaction or only a continuing ownership map? 6
KPTI — Millennium-linked investors	Sep. 4 / Aug. 31	Reported 1,297,297 shares at 5.7%	Shared voting and dispositive power; no transaction details disclosed	Does the next report add transaction evidence? 7

The table separates dates because a filing's availability date answers when the market could first read the disclosure. The underlying date answers when the reported sale, acquisition, agreement, or ownership measurement occurred.

The executed sale: KIDS

Squadron Capital's amended Schedule 13D is the week's clearest open-market sell. The filing was available on September 1, while the reported sales ran from August 24 through September 1. Squadron sold 4,000 shares at a weighted average of $25.75 on August 24, 16,300 at $24.74 on August 25, 18,000 at $24.28 on August 26, 326,700 at $23.04 on August 28, and 10,131 at $23.10 on September 1. The five lines total 375,131 shares. 1

The filing says Squadron used the sale proceeds to supply capital for other portfolio businesses. Squadron still directly held 6,526,633 shares, or 25.0%, after the reported sales. The disclosure supports a trim and a possible continuation question; it supports a full exit only after a later filing shows that the remaining block has been sold. 1

Follow-up: watch for the next Squadron amendment and compare its transaction dates with the remaining 25.0% direct position.

Financing exposure: VBIO

3i and its affiliates disclosed a different kind of position in Valion Bio. The September 2 Schedule 13D/A reports 133,005 shares, or 9.9%, based on 1,285,626 shares outstanding. The reported position combines 87,248 common shares with 45,757 shares issuable through warrants, a senior secured convertible note, and preferred stock. The instruments carry a 9.99% beneficial-ownership cap. 2

On August 31, 3i acquired 100 Series B preferred shares, 7,637 Series C preferred shares, and warrants for 3,077 plus 1,053,969 common shares, with both warrant tranches priced at $3.62. The aggregate purchase price was $7,737,000. Valion Bio received $1,500,000; the balance was retained for true-up payments and legal fees. A 1-for-25 reverse split became effective on the same date, and the filing's figures already reflect that split. 2

Follow-up: track conversion, warrant exercise, and the ownership-cap mechanics separately from common-stock buying. The filing shows active financing exposure and potential share issuance; it does not describe a conventional open-market common-stock purchase.

Control and governance: GPRK and VNRX

GeoPark's amended Schedule 13D describes a proposed control transaction. Colden Investments reported 17,915,791 shares, or 27.6%, and Jaime Gilinski reported 18,115,791 shares, or 27.9%. An affiliate, Panamerican Energy Holdings, agreed to sell 95% of Energy Assets International to GeoPark. The consideration is 42,135,872 to 47,557,461 newly issued GeoPark shares, depending on Venezuela's CIT rate. 3

The agreement gives approval rights while ownership remains at least 15%. Board nomination rights scale from one seat at 7.5% ownership to at least five seats at 50% or more. After closing, the buyer must launch a tender offer at $12.22 per share, capped at $100 million; a second tender offer is required if ownership later exceeds 70%. Approvals, licenses, and the effectiveness of Venezuela's Production Participation Contract remain part of the closing path. 3

Follow-up: treat the next approval, closing, or tender-offer filing as the next evidence point. The September 4 disclosure describes a proposed transaction and governance rights rather than an executed open-market trade.

VolitionRx's September 4 Schedule 13D presents a governance posture. Lagoda Investment Management and its affiliates reported 1,652,005 shares, or 7.4%, consisting of 1,480,950 common shares and 171,055 warrant shares. The filing records approximately $10,970,373 of aggregate purchase consideration and zero common-stock transactions during the preceding 60 days. 4

The underlying event date is August 17, before the current window. The September 4 filing is newly available in the window and matters because Lagoda moved from Schedule 13G to Schedule 13D after Fatima Dickey sent a board letter supporting management while recommending lower executive compensation and lower operating expenses. The disclosure changes the governance signal; it does not establish a new position build during this week. 4

Follow-up: read the next proxy, board letter, or amendment for a concrete governance proposal and any separate transaction disclosure.

Mechanical exit and passive maps

Spark Capital's ETOR filing records an exit from the reporting group through distributions and a small completed sale. Spark Capital II distributed 3,559,007 shares pro rata without consideration, while Spark Capital Founders' Fund II distributed 23,280 shares pro rata without consideration. Spark Capital Partners became record holder of 5,783 shares and sold all 5,783 at a weighted average of $28.01 for aggregate proceeds of $162,000. Spark entities then reported zero beneficial ownership, while director Santo Politi retained 2,107 shares. 5

Follow-up: separate the 3.58 million-share distribution from the 5,783-share market sale. The filing describes a reporting-group exit and a small completed sale, while the distribution itself carried no consideration.

Millennium-linked entities reported 5.3% ownership in Fortress Biotech in a Schedule 13G available September 1. The filing assigns voting and dispositive power on a shared basis and reports zero sole power. The filing provides an ownership map without a transaction schedule. Related reporting-person lines may describe the same block, so the figures should be read as one reported position rather than added together. 6

Karyopharm's Schedule 13G, available September 4, gives a second passive-map example. Millennium-linked investors reported 1,297,297 shares, or 5.7%, with shared voting and dispositive power and no sole power. The filing supplies no transaction details. 7

Follow-up: wait for a filing with a transaction table, an amended ownership percentage tied to a stated event, or a change in filing purpose before treating either 13G as a directional buy or sell.

What deserves another look

KIDS: compare the next Squadron transaction dates with the 6,526,633-share residual position.
VBIO: follow conversion and warrant exercise disclosures, then separate issued common shares from issuable securities.
GPRK: monitor approvals, closing conditions, the $12.22 tender offer, and the share-issuance range.
VNRX: watch for a specific governance proposal after the move from 13G to 13D.
ETOR: distinguish future market sales from the completed pro rata distributions.
FBIO and KPTI: look for transaction evidence beyond the threshold ownership maps.

The week's filings point in different directions because they record different events. KIDS supplies executed sale evidence. VBIO supplies financing and conversion exposure. GPRK supplies a proposed control path, VNRX a governance stance, ETOR a distribution-driven exit, and FBIO and KPTI passive ownership maps. The next useful filing is the one that adds a transaction, approval, conversion, or governance action to the current record.

References

1
OrthoPediatrics Schedule 13D/A
stocktitan.net
2
Valion Bio Schedule 13D/A
stocktitan.net
3
GeoPark Schedule 13D/A
stocktitan.net
4
VolitionRx Schedule 13D
stocktitan.net
5
eToro Schedule 13D/A
stocktitan.net
6
Fortress Biotech Schedule 13G
stocktitan.net
7
Karyopharm Therapeutics Schedule 13G
stocktitan.net